This release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "could," "potential," "positions," "continue," "expects," "anticipates," "intends," "plans," "believe," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the plans to move our Alzheimer's disease development program forward, our intent to conduct another clinical study in Alzheimer's disease patients age 70 and over, the use of zinc as a potential dietary management for cognitive deficits in Alzheimer's patients, the limitations inherent in post-hoc interpretations of clinical study results, the size of the Alzheimer's population, our intent to further commercialize development of reaZin as a prescription medical food, the size and evaluation time of the anticipated clinical study and the expected results of the larger clinical study with regard to the loss of cognition. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Adeona's forward-looking statements include, among others, our failure to successfully commercialize reaZin for the management of Alzheimer's disease, the failure of reaZin to be accepted for dietary management of Alzheimer's disease, failure of future clinical studies evaluating reaZin to have favorable results, and other factors described in Adeona's report
|SOURCE Adeona Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved